Berenberg analyst Victoria Lambert initiated coverage of Richter Gedeon with a Buy rating and HUF 9,980 price target. The company is best known for its original blockbuster drug Vraylar, which it sells in partnership with AbbVie in the U.S., the analyst tells investors in a research note. The firm says the market is underappreciating the earnings upside potential from Vraylar.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RGEDF: